版本:
中国

BRIEF-Galena biopharma - currently enrolling HER2 1+ and 2+ node positive

Sept 29 Galena Biopharma Inc :

* Currently enrolling HER2 1+ and 2+ node positive, high-risk node negative patients to study NeuVax in combination with trastuzumab Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐